Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
RPRX Stock Chart & Stats
$41.39
$0.10(0.38%)
At close: 4:00 PM EST
$41.39
$0.10(0.38%)
Day’s Range― - ―
52-Week Range$25.77 - $41.24
Previous CloseN/A
Volume726.99K
Average Volume (3M)3.68M
Market Cap
$23.47B
Enterprise Value$0.00
Total Cash (Recent Filing)$955.04M
Total Debt (Recent Filing)$8.97B
Price to Earnings (P/E)23.2
Beta0.20
Next Earnings
Feb 17, 2026EPS Estimate
1.26Next Dividend Ex-DateN/A
Dividend Yield2.23%
Share Statistics
EPS (TTM)1.17
Shares Outstanding427,247,500
10 Day Avg. Volume1,986,566
30 Day Avg. Volume3,684,437
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)1.64
Price to Sales (P/S)5.03
P/FCF Ratio4.11
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$49.00Price Target Upside18.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Portfolio ExpansionRPRX is in the early stages of a multi-year portfolio expansion that is underappreciated in the context of a large, growing market for royalty funding, with additional potential tailwinds from China biotech innovation trends.
Price Target IncreaseThe price target for Royalty Pharma PLC has been increased from $42.00 to $45.00.
Topline Growth ProjectionRPRX's total royalty receipts, a proxy for the company's topline, are expected to grow significantly, representing a compound annual growth rate of 8.7%.
Bears Say
Royalty Pharma News
RPRX FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $25.77 and its highest was $41.24 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Royalty Pharma PLC’s market cap is $23.47B.
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is Feb 17, 2026 which is in 39 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on Nov 05, 2025. The company reported $1.173 earnings per share for the quarter, beating the consensus estimate of $0.994 by $0.179.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC pays a Quarterly dividend of $0.22 which represents an annual dividend yield of 2.23%. See more information on Royalty Pharma PLC dividends here
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is 1.26.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 427,247,500 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $1.173 in its last earnings report, beating expectations of $0.994. Following the earnings report the stock price went up 6.83%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Currently, no hedge funds are holding shares in RPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Royalty Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.00 (18.39% Upside)
$49.00 (18.39% Upside)
Blogger Sentiment
Bullish
RPRX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 13.6%
Last 30 Days ▲ 13.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.95%
12-Months-Change
Fundamentals
Return on Equity
11.51%
Trailing 12-Months
Asset Growth
7.23%
Trailing 12-Months
Company Description
Royalty Pharma PLC
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
RPRX Company Deck
RPRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Royalty Pharma reported a strong financial performance with significant growth and strategic acquisitions in the third quarter of 2025, leading to an upward revision of its full-year guidance. Despite challenges such as the upcoming decline in Promacta royalties and increased interest expenses, the company's diversified portfolio and pipeline expansion underline its growth potential.View all RPRX earnings summariesRPRX Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
RPRX Stock 12 Month Forecast
Average Price Target
$49.00
▲(18.39% Upside)
Technical Analysis
Ownership Overview
1.80% Insiders
18.51% Mutual Funds
27.49% Other Institutional Investors
41.25% Public Companies and
Individual Investors